^
BIOMARKER:

RET mutation

i
Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive
:
A1
RET mutation
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive
:
A2
RET mutation
Thyroid Gland Medullary Carcinoma
TPX-0046
Sensitive
:
C2
RET mutation
Non Small Cell Lung Cancer
TPX-0046
Sensitive
:
C2
RET mutation
Non Small Cell Lung Cancer
BOS-172738
Sensitive
:
C2
RET mutation
Thyroid Gland Medullary Carcinoma
BOS-172738
Sensitive
:
C2
RET mutation
Thyroid Gland Medullary Carcinoma
RET inhibitor
Sensitive
:
C3
RET mutation
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
C3
RET mutation
Melanoma
Immunotherapy
Sensitive
:
C3
RET mutation
Thyroid Gland Carcinoma
LDD-2633
Sensitive
:
D
RET mutation
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive
:
D
RET mutation
Thyroid Gland Carcinoma
CB-228 + AST-487
Sensitive
:
D
RET mutation
Thyroid Gland Carcinoma
AST-487
Sensitive
:
D